Abcam, ab265387, Human LITAF knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
LITAF KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 2. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 2,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-LITAF, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The LITAF protein also known as Lipopolysaccharide-induced TNF factor plays an important mechanical role in cellular function. It has a molecular mass of approximately 18 kDa and is prevalent in various tissues particularly within the immune system. LITAF influences the process of ubiquitination by interacting with other proteins which impacts cellular response to external stimuli. The protein contains a conserved region that facilitates interaction with ubiquitin ligases and also plays a role in the degradation of misfolded proteins.
Biological function summary
The function of LITAF extends to the regulation of inflammation. This protein acts by modulating the transcription of pro-inflammatory cytokines including TNF-alpha. As part of complexes LITAF may work in collaboration with other molecules to regulate these inflammatory responses. This regulation is vital for maintaining balance within immune responses playing a significant part in defending against hostile pathogens while avoiding excessive tissue damage caused by inflammation.
Pathways
The immune and inflammatory responses prominently feature the LITAF protein. It plays a role in the TNF signaling pathway where it helps regulate the expression of tumor necrosis factor and other inflammatory mediators. LITAF is closely related to molecules like TRAF and NF-kB within these pathways facilitating various immune functions and responses. These interactions are essential for correct signaling and action during immune challenges.
Researchers have linked LITAF to conditions such as Charcot-Marie-Tooth disease and inflammatory bowel disease. The protein's involvement with TNF-alpha links it to chronic inflammation contributing to the pathogenesis of these disorders. Studies suggest that dysregulation or mutations in LITAF may affect the normal inflammatory response further connecting with proteins such as NF-kB to exacerbate symptoms of these diseases. Understanding LITAF's role in these conditions could help in developing therapeutic strategies to manage such disorders.